Q2 Earnings Forecast for CDTX Issued By HC Wainwright

Cidara Therapeutics, Inc. (NASDAQ:CDTX) – Analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of Cidara Therapeutics in a research note issued to investors on Wednesday, June 18th. HC Wainwright analyst S. Nik anticipates that the biotechnology company will post earnings per share of ($2.11) for the quarter. HC Wainwright has a “Buy” rating and a $41.00 price target on the stock. The consensus estimate for Cidara Therapeutics’ current full-year earnings is ($8.74) per share. HC Wainwright also issued estimates for Cidara Therapeutics’ Q3 2025 earnings at ($1.40) EPS, Q4 2025 earnings at ($1.46) EPS, FY2025 earnings at ($6.43) EPS, FY2026 earnings at ($6.03) EPS and FY2027 earnings at ($6.53) EPS.

CDTX has been the topic of several other reports. Needham & Company LLC boosted their target price on Cidara Therapeutics from $36.00 to $54.00 and gave the stock a “buy” rating in a report on Monday. Guggenheim lifted their price target on Cidara Therapeutics from $50.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday. WBB Securities reiterated a “strong-buy” rating and issued a $45.00 price target on shares of Cidara Therapeutics in a research note on Monday. Royal Bank Of Canada raised their price objective on shares of Cidara Therapeutics from $35.00 to $75.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Citizens Jmp started coverage on shares of Cidara Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $46.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $53.71.

Cidara Therapeutics Stock Up 4.2%

Cidara Therapeutics stock opened at $46.84 on Monday. Cidara Therapeutics has a twelve month low of $10.14 and a twelve month high of $56.83. The company has a market capitalization of $587.84 million, a P/E ratio of -1.59 and a beta of 0.79. The stock’s 50 day moving average is $23.26 and its 200 day moving average is $22.34.

Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Thursday, May 8th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.45) by $3.79.

Hedge Funds Weigh In On Cidara Therapeutics

Hedge funds have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Cidara Therapeutics during the 4th quarter valued at about $56,000. Northern Trust Corp lifted its position in Cidara Therapeutics by 6.8% during the fourth quarter. Northern Trust Corp now owns 33,957 shares of the biotechnology company’s stock valued at $913,000 after purchasing an additional 2,170 shares during the period. Point72 Asset Management L.P. purchased a new stake in Cidara Therapeutics in the fourth quarter worth approximately $165,000. OMERS ADMINISTRATION Corp boosted its holdings in Cidara Therapeutics by 53.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 19,300 shares of the biotechnology company’s stock worth $416,000 after purchasing an additional 6,700 shares during the last quarter. Finally, American Century Companies Inc. bought a new stake in Cidara Therapeutics in the 1st quarter worth approximately $224,000. Hedge funds and other institutional investors own 35.82% of the company’s stock.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.